Vivus (VVUS.Q) jumps 47% after FDA approval of improved Pancreaze pancreatic medication

If you’ve had your eye off the biotech sector recently because it doesn’t directly involve gold or cannabis, you’re missing out on one of the better casinos out there. For the high risk, high reward investor, nothing is quite like the thrill of correctly picking when a long, drawn out, US Food and Drug Administration process of approving a new drug finally gets over the line.

Nano One Materials (NNO.V) raising money at $1.15 while stock runs to $1.45

BC-based battery metals developer Nano One Materials (NNO.V) has long been a favourite at Equity.Guru – in fact, it’s been the stock we’ve held longest out of all the companies we hold. That’s been a wise decision, as we’ve watched it roll from $0.50 a few years back to $1.15 more recently, but the one beef we’ve long had with the Nano crowd is, they’re very operation-focused and can, at times, forget about the stock for extended periods while they continue to prove out their tech and advance some large scale partnerships.